|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 功能性电刺激在步态功能恢复中的技术进展(英文)显示文摘回顾了近几十年功能性电刺激在步态恢复中的技术进展。功能性电刺激干预的目的是对运动障碍(例如中风、脊髓损伤、多发性硬化症及其他)的人群进行功能性地步态恢复与康复治疗。近几年由于微纳米电子科技的快速发展,此项技术已被广泛应用到实际当中。综述涵盖了在学术界研究开发和目前市场上可用的神经假肢,并对这些系统进行了深入地分析与讨论。尤其强调了传感技术和控制策略在系统中的应用,展望了该研究领域的发展前景,并提出结合功能性电刺激与机械外骨骼作为一项新兴方法来解决目前基于功能性电刺激的神经假肢研究中的困难问题。 | 孟琳 Bernd Porr Henrik Gollee | 2017 | 仪器仪表学报2017，38，6： | 6 |
| 2 | A phase 3,double-blind,randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaı¨ve patients with mCRPC in China,Malaysia,Thailand and Russia显示文摘Objective:This double-blind,placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate+prednisone(abiraterone)to prednisone alone in chemotherapy-naı¨ve,asymptomatic or mildly symptomatic metastatic castrationresistant prostate cancer(mCRPC)patients from China,Malaysia,Thailand and Russia.Methods:Adult chemotherapy-naı¨ve patients with confirmed prostate adenocarcinoma,Eastern Cooperative Oncology Group(ECOG)performance status(PS)grade 0e1,ongoing androgen deprivation(serum testosterone<50 ng/dL)with prostate specific antigen(PSA)or radiographic progression were randomized to receive abiraterone acetate(1000 mg,QD)t prednisone(5 mg,BID)or placebo t prednisone(5 mg,BID),until disease progression,unacceptable toxicity or consent withdrawal.Primary endpoint was improvements in time to PSA progression(TTPP).Results:Totally,313 patients were randomized(abiraterone:n Z 157;prednisone:n Z 156);and baseline characteristics were balanced.At clinical cut-off(median follow-up time:3.9 months),80% patients received treatment(abiraterone:n Z 138,prednisone:n Z 112).Median time to PSA progression was not reached with abiraterone versus 3.8 months for prednisone,attaining 58%reduction in PSA progression risk(HR=0.418;p<0.0001).Abirateronetreated patients had higher confirmed PSA response rate(50%vs.21%;relative odds=2.4;p<0.0001)and were 5 times more likely to achieve radiographic response than prednisonetreated patients(22.9%vs.4.8%,p=0.0369).Median survival was not reached.Most common(≥10% abiraterone vs.prednisone-treated)adverse events:bone pain(7%vs.14%),pain in extremity(6%vs.12%),arthralgia(10%vs.8%),back pain(7%vs.11%),and hypertension(15%vs.14%).Conclusion:Interim analysis confirmed favorable benefit-to-risk ratio of abiraterone in chemotherapy-naı¨ve men with mCRPC,consistent with global study,thus supporting use of abiraterone in this patient population. | Dingwei Ye Yiran Huang Fangjian Zhou Keji Xie Vsevolod Matveev Changling Li Boris Alexeev Ye Tian Mingxing Qiu Hanzhong Li Tie Zhou Peter De Porre Margaret Yu Vahid Naini Hongchuan Liang Zhuli Wu Yinghao Sun | 2017 | Asian Journal of Urology2017，4，2： | 3 |
| 3 | Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2α 显示文摘 | Porres J C | 1994 | Hepatol1994，8，： | 1 |
| 4 | Interferon antibod- ies in patients with chronic HBV infection treated with recombi- nant interferon显示文摘 | PORRES JC CARRENO V RUIZ M | 1989 | J Hepatol1989，8，3： | 1 |
| 5 | Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia:results from a post hoc analysis of a randomized phase DI study显示文摘 | He J Xiu L De Porre P | 2014 | Leuk Lymphoma2014，56，4： | 1 |
| 6 | Postcholecystectomy syndromes and magnesium deficiency显示文摘 | Porr PJ Sza' ntay J Rusu M | 2004 | J Am Coil Nutr2004，23，6： | 1 |
| 7 | Functional expression of keratinase (kerA)gene from Bacillus licheniformis in Pichia pastoris 显示文摘 | Porres J M Benito M J Lei X G | 2002 | Biotechnology Letters2002，24，8： | 1 |
| 8 | Recombinant interferon-γ as adjuvant to hepatitis B vaccine in hemodialysis patients 显示文摘 | QUIROGA J A CASTILLO I PORRES J C | 1990 | Hepatology1990，12，4： | 1 |
| 9 | Treatment of chronic delta infection with recombinant human interfer on alpha 2c at high doses显示文摘 | Porres JC Carreno V Bartolome J | 1989 | J Hepatol1989，9，3： | 1 |
| 10 | (Comparison systemiccytokine levels in patients with acute respiratory distress svmliome,severe pneumonia,and controls显示文摘 | Baurr TT Monton C/Porres A <*t a 1 | 2000 | Thmax2000，55，1： | 1 |
| 11 | Lhemitte-Duclos dis-ease(Dysplastic gangliocytoma of the cerebellum)显示文摘 | Nowak DA Trost HA Porr A | 2001 | Clin Neurol Neurosurg2001，103，2： | 1 |
| 12 | Phytase enzymology, applications, and biotechnology显示文摘 | Lei X G Porres J M | 2003 | Biotechnology Letters2003，25，21： | 1 |
| 13 | Fever unmasking the Brugada syndrome显示文摘 | Porres JM Brugada J Urbistondo V | 2002 | Pacing Clin Electrophysiol2002，25，11： | 1 |
| 14 | Simulation and data reconstruction for NDT phased array techniques 显示文摘 | Chatillon S de Roumilly L Porre J | 2006 | Ultrasonics2006，44，： | 1 |
| 15 | Synthesis and photophysical properties of new conjugated fluorophores designed for two-photon-excited fluorescence显示文摘 | Mongin O Porres L Moreaux L | 2002 | Org Lett2002，4，5： | 1 |
| 16 | Dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease) 显示文摘 | Nowak DA Trost HA Porr A | 2001 | Clin Neurol Neurosurg2001，103，： | 1 |
| 17 | High-pressure Raman spectroscopy study of wurtzite ZnO 显示文摘 | Decremps F Porres J P Saitta A M | 2002 | Phys Rev B2002，65，09： | 1 |
| 18 | Authoring and verification of clinical guidelines: A model driven approach 显示文摘 | BEATRIZ PEREZ IVAN PORRES | 2010 | Journal of biomedical informatics2010，43，4： | 1 |
| 19 | Synthesis and two-photon absorption of highly soluble three-branched flu- orenylene-vinylene derivatives显示文摘 | Mongin Olivier Porres Laurent Katan Claudine | 2003 | Tetrahedron Letters2003，44，44： | 1 |
| 20 | Treatment of chronic delta infection with recombinant interferon alpha 2c at high doses显示文摘 | Porres JC Carreno V Bartolome J | 1998 | J Hepatol1998，9，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员